Veraxa director reports 700,000 VRXA shares

Veraxa Biotech Holding AG director Warren Hosseinion has filed an initial Form 3 reporting holdings in the company.

Rhea-AI Filing Summary

Veraxa Biotech Holding AG director Warren Hosseinion has filed an initial Form 3 reporting holdings in the company. The filing shows direct ownership of 700,000 Ordinary Shares as of June 9, 2026. This is a baseline disclosure of existing ownership rather than a new buy or sell transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hosseinion Warren

Role Director

Type	Security	Shares	Price	Value
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Ordinary Shares — 700,000 shares (Direct)

Key Figures

Ordinary Shares held: 700,000 shares

1 metrics

Ordinary Shares held 700,000 shares Direct ownership as of June 9, 2026

Key Terms

Form 3, Ordinary Shares, beneficial ownership

3 terms

Form 3 regulatory

"has filed an initial Form 3 reporting holdings in the company"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Ordinary Shares financial

"direct ownership of 700,000 Ordinary Shares as of June 9, 2026"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

beneficial ownership financial

"This is an initial ownership statement, establishing his reported stake"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Veraxa Biotech (VRXA) Form 3 filing show for Warren Hosseinion?

The Form 3 filing shows that director Warren Hosseinion directly holds 700,000 Ordinary Shares of Veraxa Biotech Holding AG. This is an initial ownership statement, establishing his reported stake as of June 9, 2026, without indicating a recent trade.

Did Warren Hosseinion buy or sell Veraxa Biotech (VRXA) shares in this Form 3?

No recent buy or sell is indicated in this Form 3. The filing records existing ownership of 700,000 Ordinary Shares as of June 9, 2026, functioning as a baseline disclosure rather than reporting a new transaction in Veraxa Biotech stock.

How many Veraxa Biotech (VRXA) shares does Warren Hosseinion report on Form 3?

Warren Hosseinion reports direct ownership of 700,000 Ordinary Shares of Veraxa Biotech Holding AG. This figure reflects his position following the reported date of June 9, 2026, and is disclosed without any associated purchase or sale details in the filing.

Is Warren Hosseinion a director or officer in Veraxa Biotech (VRXA) according to the Form 3?

According to the Form 3, Warren Hosseinion is a director of Veraxa Biotech Holding AG and not listed as an officer. The filing identifies his role, then details his direct ownership of 700,000 Ordinary Shares as of June 9, 2026.

Does the Veraxa Biotech (VRXA) Form 3 include any derivative securities for Warren Hosseinion?

The Form 3 does not list any derivative securities for Warren Hosseinion. The derivative section is empty, and the only reported holding is 700,000 Ordinary Shares, making this a straightforward disclosure of common equity ownership as of June 9, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 09:58 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hosseinion Warren

(Last) (First) (Middle)

C/O 1668 S. GARFIELD AVENUE

2ND FLOOR

(Street)

ALHAMBRA CALIFORNIA 91801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/09/2026

3. Issuer Name and Ticker or Trading Symbol
Veraxa Biotech Holding AG [ VRXA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	700,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Warren Hosseinion	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)